Gammagard Liquid Baxter Healthcare Corporation - Treatment for Primary Immunodeficiency Disorders
Gammagard Liquid 10% is a ready-to-use, sterile preparation of highly purified and concentrated immunoglobulin G (IgG) antibodies. Gammagard Liquid is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity.Posted: May 2005
Related articles
- Takeda’s Gammagard Liquid Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - January 29, 2024
- Baxter Announces FDA Approval for Gammagard Liquid as a Treatment for Multifocal Motor Neuropathy - June 26, 2012
- Baxter Announces FDA Approval of Subcutaneous Route of Administration for Gammagard Liquid for Patients with Primary Immunodeficiency - July 25, 2011
Gammagard Liquid (immune globulin infusion (human)) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
